James D. Brooks

Publication Details

  • Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

    King CR, Brooks JD, Gill H, Presti JC. Int J Radiat Oncol Biol Phys. 2012; 82 (2): 877-82

    Hypofractionated radiotherapy has an intrinsically different normal tissue and tumor radiobiology. The results of a prospective trial of stereotactic body radiotherapy (SBRT) for prostate cancer with long-term patient-reported toxicity and tumor control rates are presented.

    PubMedID: 21300474

Stanford Medicine Resources:

Footer Links: